Albumin News and Research

RSS

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

Cytrx releases statement in response to two recent lawsuits

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders:

27 Mar 2014

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA.

25 Mar 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

New scientific blood analysis predicts short-term mortality in humans

The general state of a person's metabolism can be diversely illustrated with a new scientific blood analysis. With the aid of the analysis biomarkers predicting short-term mortality have now been discovered

26 Feb 2014

Active ingredient in vinegar can effectively kill mycobacteria

The active ingredient in vinegar, acetic acid, can effectively kill mycobacteria, even highly drug-resistant Mycobacterium tuberculosis, an international team of researchers from Venezuela, France, and the US reports in mBio-, the online open-access journal of the American Society for Microbiology.

25 Feb 2014

Predictors of bone metastasis, skeletal events in lung cancer identified

Researchers have identified a range of factors that are associated with the likelihood that a patient with advanced lung cancer will develop bone metastases or skeletal-related events.

20 Feb 2014

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Many vaccines, including those for influenza, polio, and measles, consist of a killed or disabled version of a virus. However, for certain diseases, this type of vaccine is ineffective, or just too risky.

18 Feb 2014

Novel method for determining diffusion coefficients of analytes in fluids and equilibrium constants of reactions

How strongly do two dissolved analytes react with each other? Such information is of paramount importance not only in chemistry and molecular biology, but also in medicine or pharmacy, where it is used, i.a., to determine optimal drug doses. A method developed in the Institute of Physical Chemistry of the Polish Academy of Sciences in Warsaw will allow for determining diffusion coefficients of analytes in fluids and equilibrium constants of reactions - quickly, at low cost, and most importantly: universally.

14 Feb 2014

Morning blood pressure tied to target-organ damage

Physicians should ask patients to take home blood pressure readings in the morning as well as the evening before making therapeutic decisions, say researchers.

3 Feb 2014

New data on extending the serum half-life of albumin in vivo announced by Novozymes Biopharma

...

27 Jan 2014

New study examines factors that may lead to end stage renal disease

About 33 percent of people with type 2 diabetes suffer kidney damage that progresses to end stage renal disease, at which point they require either dialysis or kidney transplantation. Scientists have thought that this kidney disease is driven by damage to the glomeruli, blood vessels in the kidney, which spill the protein albumin into the urine. Current treatments targeting the resulting "albuminuria" do not prevent kidney failure.

15 Jan 2014

Research findings provide insights into risks associated with isolated mild hyperglycemia

Despite having mild hyperglycemia for approximately 50 years, patients with a mutation in the gene encoding the enzyme glucokinase had a low prevalence of clinically significant vascular complications, findings that provide insights into the risks associated with isolated mild hyperglycemia, according to a study in the January 15 issue of JAMA.

15 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Co-culture with mesenchymal stem cells results in improved viability, function of human hepatocytes

Hepatocyte transplantation is becoming an accepted therapy for acute liver failure, either for liver regeneration or as a bridge to liver transplantation. However, maintaining the viability and functional aspects of hepatocytes has been a concern even with successful freezing.

19 Dec 2013

First Nations adults with diabetes more likely to face risk of end-stage kidney disease

First Nations adults with diabetes have more than double the risk of end-stage kidney disease compared with non-First Nations adults, found a new study in CMAJ (Canadian Medical Association Journal).

3 Dec 2013

Hypertension organ risk revealed in Chinese patients

A study of Chinese patients warns of the risk for target organ damage from untreated hypertension, especially for younger patients.

2 Dec 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

Albumin News and Research

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Bariatric surgery patients report better quality of life

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Cytrx releases statement in response to two recent lawsuits

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

New scientific blood analysis predicts short-term mortality in humans

Active ingredient in vinegar can effectively kill mycobacteria

Predictors of bone metastasis, skeletal events in lung cancer identified

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Novel method for determining diffusion coefficients of analytes in fluids and equilibrium constants of reactions

Morning blood pressure tied to target-organ damage

New data on extending the serum half-life of albumin in vivo announced by Novozymes Biopharma

New study examines factors that may lead to end stage renal disease

Research findings provide insights into risks associated with isolated mild hyperglycemia

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Co-culture with mesenchymal stem cells results in improved viability, function of human hepatocytes

First Nations adults with diabetes more likely to face risk of end-stage kidney disease

Hypertension organ risk revealed in Chinese patients

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News